InspireMD, Inc.: InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory

Related Keywords

Israel ,United States ,America ,Marvin Slosman ,Andrea Tommasoli ,Chuck Padala ,Company Ce Mark ,Nasdaq ,Exchange Commission ,Drug Administration ,Inspiremd Inc ,Company Vice ,Company Annual Report On Form ,Medical Device Directive ,Medical Device Regulation ,Embolic Prevention System ,Recent Developments ,Shane Gleason ,General Manager ,North America ,Vice President ,Global Marketing ,Global Sales ,Chief Operating Officer ,C Guardian Investigational Device Exemption ,Switchguard Trans Carotid ,Prime Transfemoral ,Fourth Quarter ,Annual Report ,Quarterly Reports ,Wall December ,Inspiremd ,Reports ,Fourth ,Quarter ,Ear ,022 ,Financial ,Results ,Rovides ,Business ,Update ,